HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NRXP
NRx Pharmaceuticals, Inc.
There isn't enough reported data to score NRXP yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NRXP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
NRXP's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NRXP PE Valuation
NRXP has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over NRXP on the outlook, with more favorable profitability expectations.
NRXP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect NRXP's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
NRXP has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus NRXP down 206%.
NRXP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$2.29 | -$0.12 |
| Q2 2025 | -$2.17 | +$0.55 |
| Q1 2025 | -$1.94 | +$1.23 |
| Q4 2024 | -$2.36 | +$1.67 |
| Q3 2024 | -$2.17 | +$2.83 |
| Q2 2024 | -$2.72 | +$2.98 |
| Q1 2024 | -$3.17 | +$2.43 |
| Q4 2023 | -$4.03 | +$1.97 |
NRXP is still losing money, but far less than before: $2.29 per share over the past year, against $19.00 at its worst in mid-2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NRXP on profitability, with a higher operating margin.
NRXP Quarterly Revenue
NRXP's revenue has grown year over year every quarter since late 2025: $1M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -591% | N/A |
| Q1 2026 | -444% | N/A |
| Q4 2025 | -470% | N/A |
| Q3 2025 | -1663% | N/A |
HIMS has the edge over NRXP on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
NRXP has the stronger cash trend. Its trailing FCF is up 25% versus its history, compared with HIMS at down 84%.
NRXP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.3M | -$815K |
| Q4 2025 | -$3.7M | -$1.6M |
| Q3 2025 | -$2.9M | -$585K |
| Q4 2024 | -$2.1M | +$1.1M |
| Q3 2024 | -$2.3M | +$2.3M |
| Q4 2023 | -$3.2M | +$5.1M |
| Q3 2023 | -$4.6M | +$1.7M |
| Q2 2023 | -$7.8M | +$7M |
NRXP has burned cash in almost every quarter: −$15M over the past year, against −$11M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NRXP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NRXP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +5.3M shares |
| 1 year | +118% | +20.4M shares |
| 3 years | +472% | +31.1M shares |
| 5 years | +13858% | +37.4M shares |
| Available history | +13340% | +37.4M shares |
NRXP has 38M diluted shares, up 118% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2020 | $299,253 |
| Q2 2020 | — |
| Q1 2020 | $26M |
| Q3 2019 | $8.9M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NRXP Net Leverage
NRXP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NRXP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 10.6 | Oversold |
NRXP's weekly RSI is 36 (neutral) and its Stochastic is 11 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NRXP PE vs Healthcare Sector
| Metric | NRXP | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NRXP has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NRXP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.60 | 12% below |
| 20 week MA | $3.21 | 29% below |
| 50 week MA | $2.85 | 20% below |
| 100 week MA | $2.78 | 18% below |
| 200 week MA | $3.47 | 34% below |
NRXP is in a downtrend: it's below all five of its weekly moving averages, and 34% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NRXP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $106.5 | $296.4 | +178% |
| 2021 | $296.4 | $50.4 | -83% |
| 2022 | $50.4 | $10.8 | -79% |
| 2023 | $10.8 | $4.60 | -57% |
| 2024 | $4.60 | $1.51 | -67% |
| 2025 | $1.51 | $2.56 | +70% |
| 2026 YTD | $2.56 | $2.28 | -11% |
NRXP has the edge over HIMS on returns for 2026, with the stronger performance.